BACKGROUND: Children with Crohn's disease (CD) may report abdominal pain despite clinical remission, suggesting that functional abdominal pain (FAP) may be playing a role. The aim of this study was to explore the presence and impact of FAP in children with CD in remission. METHODS: Children, aged 9 to 17 years, with CD were enrolled. Demographic information, the Pediatric Crohn's Disease Activity Index, and the Children's Depression Inventory were obtained. Disease remission was defined by physician global assessment, normal laboratories findings, absence of 3 or more stools a day, nocturnal stooling, bloody diarrhea, concurrent steroid therapy, strictures, or disease flare within 6 months. FAP was defined as patients with abdominal pain and CD remission. Rates of depression (Children's Depression Inventory >9) were compared. RESULTS: Of 307 children, 139 reported abdominal pain. Of this group, 18 of 139 (13%) children met the criteria for FAP. Despite clinical remission, 8 of 18 patients with CD having FAP were classified with active disease by Pediatric Crohn's Disease Activity Index. These patients had a higher rate of depression than patients with CD in remission with no abdominal pain (55.6% versus 29.9%; P = 0.03), similar to patients with abdominal pain from active CD (55.6% versus 44.8%; P = 0.62). CONCLUSIONS: A proportion of children with CD in remission have FAP. These children are at significant risk of depression. Future studies are needed to determine whether depression contributes to functional pain development or if pain itself leads to depression. Especially given that functional pain may exaggerate disease activity, clinicians caring for children with CD and FAP should consider evaluating for depressive disorders before escalating therapy.
BACKGROUND:Children with Crohn's disease (CD) may report abdominal pain despite clinical remission, suggesting that functional abdominal pain (FAP) may be playing a role. The aim of this study was to explore the presence and impact of FAP in children with CD in remission. METHODS:Children, aged 9 to 17 years, with CD were enrolled. Demographic information, the Pediatric Crohn's Disease Activity Index, and the Children's Depression Inventory were obtained. Disease remission was defined by physician global assessment, normal laboratories findings, absence of 3 or more stools a day, nocturnal stooling, bloody diarrhea, concurrent steroid therapy, strictures, or disease flare within 6 months. FAP was defined as patients with abdominal pain and CD remission. Rates of depression (Children's Depression Inventory >9) were compared. RESULTS: Of 307 children, 139 reported abdominal pain. Of this group, 18 of 139 (13%) children met the criteria for FAP. Despite clinical remission, 8 of 18 patients with CD having FAP were classified with active disease by Pediatric Crohn's Disease Activity Index. These patients had a higher rate of depression than patients with CD in remission with no abdominal pain (55.6% versus 29.9%; P = 0.03), similar to patients with abdominal pain from active CD (55.6% versus 44.8%; P = 0.62). CONCLUSIONS: A proportion of children with CD in remission have FAP. These children are at significant risk of depression. Future studies are needed to determine whether depression contributes to functional pain development or if pain itself leads to depression. Especially given that functional pain may exaggerate disease activity, clinicians caring for children with CD and FAP should consider evaluating for depressive disorders before escalating therapy.
Authors: J S Hyams; G D Ferry; F S Mandel; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; R J Grand; J T Boyle Journal: J Pediatr Gastroenterol Nutr Date: 1991-05 Impact factor: 2.839
Authors: Magnus Simrén; Jenny Axelsson; Rolf Gillberg; Hasse Abrahamsson; Jan Svedlund; Einar S Björnsson Journal: Am J Gastroenterol Date: 2002-02 Impact factor: 10.864
Authors: Eva Szigethy; Anna Levy-Warren; Sarah Whitton; Athos Bousvaros; Kimberlee Gauvreau; Alan M Leichtner; William R Beardslee Journal: J Pediatr Gastroenterol Nutr Date: 2004-10 Impact factor: 2.839
Authors: Itta M Minderhoud; Bas Oldenburg; Josta A Wismeijer; Gerard P van Berge Henegouwen; André J P M Smout Journal: Dig Dis Sci Date: 2004-03 Impact factor: 3.199
Authors: Sunanda V Kane; William J Sandborn; Paul A Rufo; Anna Zholudev; James Boone; David Lyerly; Michael Camilleri; Stephen B Hanauer Journal: Am J Gastroenterol Date: 2003-06 Impact factor: 10.864
Authors: Arvind I Srinath; Alka Goyal; Lori A Zimmerman; Melissa C Newara; Margaret A Kirshner; Francis Nicole McCarthy; David Keljo; David Binion; Athos Bousvaros; David R DeMaso; Ada Youk; Eva M Szigethy Journal: Inflamm Bowel Dis Date: 2014-08 Impact factor: 5.325
Authors: Robyn Lewis Claar; Miranda A L van Tilburg; Bisher Abdullah; Shelby Langer; Dalia Sherif; William E Whitehead; Douglas A Drossman; Rona L Levy Journal: J Pediatr Gastroenterol Nutr Date: 2017-10 Impact factor: 2.839
Authors: Bonney Reed-Knight; Miranda A L van Tilburg; Rona L Levy; Shelby L Langer; Joan M Romano; Tasha B Murphy; Melissa M DuPen; Andrew D Feld Journal: J Pediatr Psychol Date: 2018-01-01
Authors: Andrée Rasquin; Carlo Di Lorenzo; David Forbes; Ernesto Guiraldes; Jeffrey S Hyams; Annamaria Staiano; Lynn S Walker Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: Anava A Wren; Rachel Bensen; Lindsay Sceats; Melody Dehghan; Helen Yu; Jessie J Wong; Donna MacIsaac; Zachary M Sellers; Cindy Kin; K T Park Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 7.290